No difference in cancer-specific mortality was observed between factor Xa inhibitors (1,028/23,711; 4.34%, 95% CI [4.02%,4.68%]) and dabigatran (1,001/23,715; 4.23%, 95% CI [3.83%,4.66%]; SHR 1.03, 95% CI [0.94,1.12]) treatments. This evidence concerns the gene F10 and cancer.